ZNTL
NASDAQ · Biotechnology
Zentalis Pharmaceuticals Inc
$2.39
+0.18 (+8.14%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 27.61M | 25.42M | 27.85M |
| Net Income | -2,223,610 | -1,538,415 | -1,953,169 |
| EPS | — | — | — |
| Profit Margin | -8.1% | -6.1% | -7.0% |
| Rev Growth | +21.3% | +16.0% | +14.0% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 11.52M | 10.77M | 11.77M |
| Total Equity | 88.47M | 80.04M | 88.96M |
| D/E Ratio | 0.13 | 0.13 | 0.13 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | -3,072,165 | -2,609,903 | -3,215,308 |
| Free Cash Flow | -1,433,660 | -1,157,693 | -1,340,683 |